WEBINAR

Detecting cancer fusion transcripts in long-read RNA-Seq data with CTAT-LR-fusion

  Americas broadcast: Wednesday, September 11, 10:00 AM PDT | 1:00 PM EDT
  Asia-Pacific broadcast: Thursday, September 12, 10:00 AM SGT

Accurate fusion gene detection is critical in cancer research, as fusion genes can serve as biomarkers or therapeutic targets. Short reads can identify fusion gene breakpoints but cannot offer isoform-resolution fusion discovery, which limits their utility. In contrast, long-read RNA sequencing using the PacBio Kinnex full-length RNA and single-cell RNA kits can offer full-length isoform information in bulk and single-cell RNA samples.

In this webinar, you will learn about CTAT-LR-fusion, a new bioinformatics tool for detecting known and novel fusion transcripts from PacBio long-read isoform sequencing data, with applications to bulk and single-cell tumor transcriptomes. Get an in-depth comparison of this innovative tool against other existing long-read fusion detection methods on simulated data, reference cancer cell lines, and patient-derived tumor samples, demonstrating its superior performance.

Register to:

  • Learn how Kinnex kits offer cost-effective, scalable, full-length isoform sequencing for both bulk and single-cell RNA.
  • Understand the advantages of Kinnex vs. short reads and other long-read technologies for fusion discovery in cancer research.
  • Hear how researchers at the Broad Institute developed CTAT-LR-fusion for cancer fusion discovery, and how it integrates with Kinnex data and other genomic tools for multi-omics analysis in cancer research.

Don’t forget to stick around and have your questions answered during a live Q&A session with the webinar speakers!


Register for webinar

By registering on this web page, you are consenting and agreeing to collection and use of your information by PacBio in accordance with its privacy policy 

Speakers

Elizabeth Tseng, PhD
Associate Director, Product Marketing, PacBio

Brian Haas, PhD
Principal Computational Scientist, Methods Development Laboratory, Broad Clinical Labs, Broad Institute of MIT and Harvard